NLS Pharmaceutics Announces Compliance With Nasdaq Bid Price Requirement
NLS Pharmaceutics Announces Compliance With Nasdaq Bid Price Requirement
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement.
瑞士秀克黎世/ACCESSWIRE/2023年1月12日/瑞士臨床階段生物製藥公司NLS製藥有限公司(納斯達克股票代碼：NLSP，NLSPW)(以下簡稱“公司”)今天宣佈，它收到了納斯達克上市資格人員的通知函，通知公司它已重新遵守納斯達克的最低投標價格要求。納斯達克是一家專注於為罕見和複雜的中樞神經系統疾病患者發現和開發創新療法的公司。
On June 10, 2022, NLS was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given a 180-day extension, or until December 5, 2022 to regain compliance. On December 6, 2022, NLS received an additional written notice from the Nasdaq Staff that the bid price requirement was not met, that NLS was not eligible for a second 180-day extension and that the bid price issue provided a separate basis for delisting of the Company's common shares.
2022年6月10日，納斯達克首次通知NLS，其未能根據納斯達克上市規則第5550(A)(2)和5810(C)(3)(A)條連續30個工作日維持每股1.00美元的最低收購價格，並被給予180天的延期，即至2022年12月5日，以重新獲得合規。2022年12月6日，NLS收到納斯達克工作人員的額外書面通知，稱NLS未達到投標價格要求，沒有資格第二次延期180天，並且投標價格問題為本公司普通股退市提供了單獨的基礎。
The letter NLS received from Nasdaq on January 10, 2023 noted that as of January 9, 2023, the Company evidenced a closing bid price of its common shares at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days, from December 20, 2022 through January 9, 2023. Nasdaq stated that accordingly, NLS has regained compliance with Nasdaq Listing Rule 5550(a)(2).
2023年1月10日收到的納斯達克的信件指出，截至2023年1月9日，該公司證明其普通股的收盤價在2022年12月20日至2023年1月9日的最後10個工作日的每股最低要求為1.00美元或更高。納斯達克表示，據此，免入息稅已恢復遵守納斯達克上市規則第5550(A)(2)條。
About NLS Pharmaceutics Ltd.
關於NLS製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS製藥有限公司(納斯達克代碼：NLSP)是一家全球開發期生物製藥公司，與世界級合作夥伴和國際公認的科學家網絡合作，專注於為患有罕見和複雜的中樞神經系統疾病的患者發現和開發創新療法，這些患者的醫療需求尚未得到滿足。NLS總部設在瑞士，成立於2015年，由一支經驗豐富的管理團隊領導，該團隊在開發和商業化候選產品方面有著良好的記錄。欲瞭解更多資訊，請訪問。
For additional information:
有關更多資訊，請訪問：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投資者和媒體)
NLS製藥有限公司。
+1 239.682.8500
郵箱：ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
資料來源：NLS製藥公司